Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 711 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Atopic Clear all
Completed Not applicable Interventional

Wool Clothing for the Management of Childhood Atopic Dermatitis (DESSINE2)

NCT04011215
View directory record Official record
Conditions
Dermatitis, Atopic
Interventions
wool clothing, standard clothing
Other
Lead sponsor
Murdoch Childrens Research Institute
Other
Eligibility
3 Months to 5 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 25, 2025 · Synced Oct 27, 2026, 5:07 AM EDT
Recruiting Phase 2 Interventional

Food-Specific and Component IgE Threshold Levels That Predict Food Allergy in People With Elevated Total Serum IgE Levels and Atopic Dermatitis

NCT03835767
View directory record Official record
Conditions
Milk and/or Peanut Allergy
Interventions
Peanut powder and Oat flour, Peanut flour and Oat flour (placebo for peanut flour), Dry Milk Powder and Corn Starch (placebo for Milk powder), Baked milk and Rice milk (placebo for Baked milk)
Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
3 Years to 21 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Recruiting No phase listed Observational

Registry for Systemic Eczema Treatments

NCT06136767
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
1 Year to 26 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Active, not recruiting Phase 2 Interventional

Phase 2a Study to Assess the Efficacy,Safety and Tolerability of GIA632 in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT07220577
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
GIA632, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
3
States / cities
Fremont, California • Rockville, Maryland • Hoboken, New Jersey
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Tolerability of XmAb®7195 in Adult Healthy Volunteers and Adult Subjects With a History of Allergic Rhinitis and/or Allergic Conjunctivitis and/or Atopic Dermatitis

NCT02148744
View directory record Official record
Conditions
Allergic Rhinitis, Allergic Conjunctivitis, Atopic Dermatitis
Interventions
XmAb7195, Placebo
Biological
Lead sponsor
Xencor, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 24, 2017 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

NCT03921411
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Nemolizumab
Biological
Lead sponsor
Galderma R&D
Industry
Eligibility
12 Years to 17 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
10
States / cities
Fountain Valley, California • Fremont, California • Jacksonville, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2023 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 2 Interventional Results available

Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis

NCT04753034
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TER-101, Vehicle
Drug
Lead sponsor
Teres Bio, Inc.
Industry
Eligibility
12 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
12
States / cities
Scottsdale, Arizona • Encinitas, California • North Miami Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Safety, Tolerability and Pharmacokinetics Study of Topical Ointment YR001 in Adult Healthy Volunteers

NCT05718921
View directory record Official record
Conditions
Atopic Dermatitis, Psoriasis
Interventions
YR001 Dose A on low body surface area, YR001 Dose A on middle body surface area, YR001 Dose A on high body surface area, YR001 Dose B on low body surface area, YR001 Dose B on middle body surface area, YR001 Dose B on high body surface area, Placebo on low body surface area, Placebo on middle body surface area, Placebo on high body surface area, YR001 Dose A on high body surface area twice daily, YR001 Dose B on high body surface area twice daily, Placebo on high body surface area twice daily
Drug
Lead sponsor
Hangzhou Yirui Pharmaceutical Technology Co., Ltd
Industry
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Encinitas, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2024 · Synced Oct 27, 2026, 5:07 AM EDT
Recruiting No phase listed Observational

This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment

NCT07290803
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Not listed
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
46
States / cities
Birmingham, Alabama • Montgomery, Alabama • Gilbert, Arizona + 43 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Pimecrolimus Cream 1% in Mild to Moderate Head and Neck Atopic Dermatitis (AD) Patients

NCT00121316
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Pimecrolimus, Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
12 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
0
States / cities
Not listed
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Oct 27, 2026, 5:07 AM EDT
Completed No phase listed Observational

Cohort Study of the Patterns of Microvesicles in the Serum of Participants With Atopic and Non-atopic Asthma

NCT00700726
View directory record Official record
Conditions
Asthma, Allergies
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 50 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 13, 2014 · Synced Oct 27, 2026, 5:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Studies of Skin Microbes in Healthy People and in People With Skin Conditions

NCT00605878
View directory record Official record
Conditions
Eczema, Atopic Dermatitis
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
2 Years to 100 Years
Enrollment
530 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Active, not recruiting Phase 2 Interventional

A Study Evaluating TRIV-509 in Atopic Dermatitis

NCT07167758
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
TRIV-509, Placebo
Drug
Lead sponsor
Triveni Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
9
States / cities
Fountain Valley, California • San Diego, California • Miami, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema

NCT02357940
View directory record Official record
Conditions
Atopic Dermatitis (AD)
Interventions
Experimental Product
Drug
Lead sponsor
Johnson & Johnson Consumer Inc. (J&JCI)
Industry
Eligibility
6 Months and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
2
States / cities
St. Petersburg, Florida • Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.

NCT04903093
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Abrocitinib tablet, Abrocitinib Suspension F1, Abrocitinib Suspension F2, Abrocitinib Suspension F3, Abrocitinib Suspension F4, Abrocitinib Suspension F5, Abrocitinib Suspension F6, Famotidine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 14, 2024 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Study of 0416 Ointment in the Treatment of Atopic Dermatitis

NCT01053247
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
0416, Vehicle of 0416 test product, tacrolimus ointment 0.1%
Drug
Lead sponsor
Fougera Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
793 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Melville, New York
Source: ClinicalTrials.gov public record
Updated Oct 3, 2014 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)

NCT03160885
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
LEO Pharma
Industry
Eligibility
18 Years and older
Enrollment
794 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
40
States / cities
Hot Springs, Arkansas • Encinitas, California • Fullerton, California + 35 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Oct 27, 2026, 5:07 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Study to Examine the Cytokine Levels, Gene Expression and Safety of a Single Nasal Dose of JNJ-43260295, in Healthy Participants, and Atopic Participants With Mild to Mild-Persistent Asthma

NCT02243189
View directory record Official record
Conditions
Healthy, Asthma
Interventions
JNJ-43260295, Placebo, Nasal Allergen Challenge
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2016 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A First-in-Human, Double Blind, Single Dose Study in Healthy Subjects and Subjects With Mild Atopic Asthma.

NCT01928368
View directory record Official record
Conditions
Asthma
Interventions
AMG 282, AMG 282 Matching Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 55 Years
Enrollment
70 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
5
States / cities
Cypress, California • Aventura, Florida • Lenexa, Kansas + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2016 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 1 Interventional

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Upadacitinib in Pediatric Participants With Severe Atopic Dermatitis

NCT03646604
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Upadacitinib (ABT-494)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 12 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
15
States / cities
Huntington Beach, California • Los Angeles, California • Coral Gables, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Oct 27, 2026, 5:07 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of REGN3500 Monotherapy and Combination of REGN3500 Plus Dupilumab in Adult Patients With Moderate-to-Severe Atopic Dermatitis

NCT03736967
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
REGN3500, Dupilumab, REGN3500 + Dupilumab Combo, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
22
States / cities
Phoenix, Arizona • Fountain Valley, California • Long Beach, California + 17 more
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Not applicable Interventional Results available

Study on the Role of Treatment With Vitamin E on Asthmatic Responses in Allergic Asthmatics

NCT00581048
View directory record Official record
Conditions
Allergic Asthma
Interventions
Natural source d-α-tocopheryl acetate
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 29, 2018 · Synced Oct 27, 2026, 5:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Metabolic Profiling of Immune Responses in Immune-mediated Diseases

NCT04864886
View directory record Official record
Conditions
Primary Immunodeficiency, Psoriasis, Atopic Dermatitis, Immune-mediated Diseases
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 75 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 27, 2026, 5:07 AM EDT
Completed Phase 3 Interventional Results available

A Study of Baricitinib (LY3009104) in Adult Participants With Moderate to Severe Atopic Dermatitis

NCT03435081
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Baricitinib, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
440 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
60
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Beverly Hills, California + 52 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2022 · Synced Oct 27, 2026, 5:07 AM EDT